Skip to search formSkip to main contentSkip to account menu

E5564

Known as: E 5564, E-5564 
National Institutes of Health

Related topics

Related topics

5 relations
B 1287analogs & derivativeseritoran

Broader (2)

Eritoran TetrasodiumLipid A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins
Lipid A, the active moiety of LPS, exerts its effects through interaction with TLR4, triggering a signalling cascade that results… 
2012
2012
A Synthetic Lipid A Mimetic Modulates Human TLR4 Activity
Innate immunity recognition relies on a diverse set of germ line encoded receptors, termed pattern recognition receptors (PRR… 
Review
2010
Review
2010
Tele-intensive care unit: the horse out of the barn.
Despite the decline in total hospital beds, the intensive care unit (ICU) beds increased from 1985 to 2000 in the United States… 
2006
2006
Syntheses of glucose derivatives of E5564-related compounds and their LPS-antagonistic activities.
Review
2004
Review
2004
Drug evaluation: E-5564.
Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological… 
2003
2003
E-5564: Treatment of septic shock, TLR4 (LPS) receptor antagonist
Sepsis, a significant cause of morbidity and mortality in all hospitalized patients, is the result of an overexaggerated host… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2000
2000
Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531
The synthetic antagonists of lipopolysaccharide (LPS), E5531 and E5564, are analogs of the lipid A portion of LPS that not only… 
1999
1999
Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)